✨ Onyx Summary Rocket Pharmaceuticals reported third-quarter 2025 results, highlighting renewed FDA alignment to resume its Phase 2 pivotal study of RP-A501 for Danon disease and ongoing progress across its AAV-based cardiovascular and lentiviral hematology gene therapy programs. The company ended the quarter with $222.8 million in cash, reduced its
✨ Onyx Summary enGene Holdings announced that management will participate in three upcoming investor conferences—the Guggenheim Healthcare Innovation, Stifel 2025 Healthcare, and Jefferies Global Healthcare Conferences—throughout November 2025. Webcasts of the presentations will be available on the company’s investor website for 90 days. BOSTON & MONTREAL – enGene Holdings
✨ Onyx Summary Guardant Health granted restricted stock units representing 184,961 shares and one stock option for 5,731 shares to new non-executive employees under its 2023 Employment Inducement Incentive Award Plan, with an exercise price of $93.02 per share. The awards, approved on October 21, 2025, serve as
✨ Onyx Summary Guardant Health released new data showing that its Guardant Reveal blood test can detect chemotherapy effectiveness in patients with advanced solid tumors months earlier than conventional methods, using a tissue-free, methylation-based ctDNA tumor fraction signal. Published in the Journal of Liquid Biopsy, the study found that decreases in
✨ Onyx Summary Seer reported third-quarter 2025 revenue of $4.1 million, up 2% year-over-year, with a net loss of $18.2 million and $251.2 million in cash and investments. The company saw record adoption of its Proteograph ONE workflow and a surge in third-party publications, underscoring expanding market validation
✨ Onyx Summary Recursion reported a third-quarter 2025 net loss of $162.3 million on $5.2 million in revenue, with $667 million in cash and an expected runway through 2027. The company achieved over $500 million in cumulative upfront and milestone payments from partners Roche, Genentech, and Sanofi, advanced multiple
✨ Onyx Summary Recursion announced a leadership transition effective January 1, 2026, with Chief R&D and Commercial Officer Najat Khan, Ph.D., appointed CEO and President, succeeding Co-Founder Chris Gibson, Ph.D., who will become Chairman of the Board and interim Executive Advisor. The move, unanimously approved by the
✨ Onyx Summary Geron reported third-quarter 2025 revenue of $47.2 million, up 67% year over year, driven by continued commercialization of RYTELO for lower-risk myelodysplastic syndromes, with a net loss of $18.4 million and $421.5 million in cash. The company completed enrollment in its Phase 3 IMpactMF trial
✨ Onyx Summary Keros Therapeutics reported a third-quarter 2025 net loss of $7.3 million, significantly reduced from $53.0 million a year earlier, driven by revenue from its licensing agreement with Takeda. The company ended the quarter with $693.5 million in cash and plans to return $375 million to
✨ Onyx Summary Foghorn Therapeutics reported third-quarter 2025 collaboration revenue of $8.2 million and a net loss of $15.8 million, ending the quarter with $180.3 million in cash and a runway extending into 2028. The company advanced its oncology pipeline—including FHD-909 in Phase 1 with Lilly and
✨ Onyx Summary Guardant Health reported new real-world data showing a 95% adherence rate for its FDA-approved Shield blood-based colorectal cancer screening test, significantly higher than traditional colonoscopy or stool-based methods. Additional findings from clinics in Appalachia showed Shield increased overall screening rates from 45% to 90%, reinforcing its role in
✨ Onyx Summary Guardant Health priced an upsized public offering of 3,333,333 shares of common stock at $90 per share, increasing the deal from the previously announced $250 million to approximately $300 million in gross proceeds, with underwriters granted an option to purchase up to 499,999 additional shares.
✨ Onyx Summary Guardant Health priced an upsized $350 million private offering of 0% convertible senior notes due 2033, increased from $300 million, with an option for an additional $52.5 million and a conversion price of approximately $121.50 per share—a 35% premium to its concurrent equity offering. The
✨ Onyx Summary Lexicon Pharmaceuticals announced that new data from three studies of sotagliflozin will be presented at the 2025 American Heart Association Scientific Sessions and the Hypertrophic Cardiomyopathy Society conference in New Orleans. The presentations will highlight sotagliflozin’s effects in heart failure and hypertrophic cardiomyopathy, reinforcing its potential differentiation
✨ Onyx Summary Recursion announced its participation in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11 and the Jefferies Global Healthcare Conference in London on November 18, 2025. Live webcasts of both events will be available on the company’s investor relations website. Salt Lake City, Nov. 04, 2025
✨ Onyx Summary Geron announced that CEO Harout Semerjian will participate in fireside chats at the Stifel 2025 Healthcare Conference on November 11 and the 8th Annual Evercore Healthcare Conference on December 2. Live and archived webcasts of both sessions will be available on the company’s investor relations website. FOSTER
